Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: An open-label, fixed-sequence study in healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6158-6164

  Vourvahis, Manoli ^a   Plotka, Anna ^b   Da Costa, Laure Mendes ^b   Fang, Annie ^a   Heera, Jayvant ^b  

^a Pf Izer Global Research and Development   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; MARAVIROC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBAMIC ACID DERIVATIVE; CYCLOHEXANE DERIVATIVE; DRUG COMBINATION; FOSAMPRENAVIR; ORGANOPHOSPHATE; RITONAVIR; SULFONAMIDE; TRIAZOLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DECREASED APPETITE; DEFECATION HABIT; DIARRHEA; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH DISEASE; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID PHASE EXTRACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; BLOOD; CLINICAL TRIAL; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CARBAMATES; CYCLOHEXANES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG DOSAGE CALCULATIONS; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHATES; RITONAVIR; SULFONAMIDES; TRIAZOLES;

EID: 84887430819     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01098-13     Document Type: Article

References (34)

1. ViiV Healthcare. 2013. Selzentry (maraviroc) prescribing information. ViiV Healthcare, Middlesex, United Kingdom. http://www.viivhealthcare.com/-/ media/Files/G/GlaxoSmithKline-Plc/pdfs/us-selzentry.pdf.
2. ViiV Healthcare. 2013. Celsentri (maraviroc): summary of product characteristics. ViiV Healthcare, Middlesex, United Kingdom. http://www .viivhealthcare.com/products/selzentry-celsentri.aspx#.
3. Abel S, Back DJ, Vourvahis M. 2009. Maraviroc: pharmacokinetics and drug interactions. Antivir. Ther. 14:607-618.
4. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. 2010. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA 304:321-333.
5. Hull MW, Montaner JS. 2011. Ritonavir-boosted protease inhibitors in HIV therapy. Ann. Med. 43:375-388.
6. Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. 2008. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br. J. Clin. Pharmacol. 65(Suppl 1):27-37.
7. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. 2008. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br. J. Clin. Pharmacol. 65(Suppl 1):38-46.
8. Kakuda TN, Abel S, Davis J, Hamlin J, Scholler-Gyure M, Mack R, Ndongo N, Petit W, Ridgway C, Sekar V, Tweedy S, Hoetelmans RM. 2011. Pharmacokinetic interactions of maraviroc with darunavirritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. Antimicrob. Agents Chemother. 55:2290-2296.
9. Weatherley B, McFadyen L, Chan PLS, Marshall S. 2008. Population pharmacokinetic covariate analysis of maraviroc in phase 2b/3 studies in treatment-experienced (TE) HIV-1-infected subjects on optimized background therapy (OBT). 9th Int. Workshop Clin. Pharmacol. HIV Ther., poster 17a.
10. Luber A, Condoluci D, Slowinksi PD, Olson K, Andrews M, Louie S, et al. 2009. Steady-state pharmacokinetics of maraviroc and amprenavir alone and in combination after maraviroc is given BID with unboosted or ritonavir-boosted fosamprenavir once- or twice-daily in fasted healthy volunteers. 10th Int. Workshop Clin. Pharmacol. HIV Ther., abstr P31.
11. ClinicalTrials.gov. 2011. Pharmacokinetic interaction between maraviroc and fosamprenavir/ritonavir in healthy subjects (NCT01140412). National Institutes of Health, Bethesda, MD. http://clinicaltrials.gov/ct2/show/ NCT01140412?term-A4001099&rank-1.
12. Blaschke TF. 2008. Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes. Curr. Opin. HIV AIDS 3:603-607.
13. Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, Rosenkranz SL, Kmack A, Ferguson E, Dehlinger M, Mildvan D. 2010. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin. Infect. Dis. 50:1041-1052.
14. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. 2005. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 6:185-190.
15. Brewer E, Felix T, Clarke P, Edgington A, Muirhead D. 2010. An LC-MS-MS method for quantitative determination of maraviroc (UK- 427,857) in human plasma, urine and cerebrospinal fluid. Biomed. Chromatogr. 24:1316-1323.
16. DHHS/CDER/CVM. 2001. Guidance for industry: bioanalytical method validation. Department of Health and Human Services/U.S. Food and Drug Administration Center for Drug Evaluation and Research/Center for Veterinary Medicine, Washington, DC. http://www.fda.gov/downloads/Drugs/Guidances/ ucm070107.pdf.
17. Andrews E, Glue P, Fang J, Crownover P, Tressler R, Damle B. 2010. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br. J. Clin. Pharmacol. 69:51-57.
18. Wire MB, Shelton MJ, Lou Y, Baker KL, Staley L, Thomas G, Berrey MM. 2004. Ritonavir (RTV) increases plasma amprenavir (APV) exposure to a similar extent when co-administered with either fosamprenavir (FPV) or APV (APV10022). 44th Int. Conf. Antimicrob. Agents Chemother., poster A-450.
19. Ramanathan S, Abel S, Tweedy S, West S, Hui J, Kearney BP. 2010. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. J. Acquir. Immune Defic. Syndr. 53:209-214.
20. Zembruski NC, Haefeli WE, Weiss J. 2011. Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob. Agents Chemother. 55:1282-1284.
21. Kakuda TN, Abel S, Davis J, Hamlin J, Scholler-Gyure M, Mack R, Ndongo N, Petit W, Ridgway C, Sekar V, Tweedy S, Hoetelmans RM. 2011. Pharmacokinetic interactions of maraviroc with darunavirritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. Antimicrob. Agents Chemother. 55:2290-2296.
22. Vourvahis M, Valluri SR, Damle B, Than S. 2010. Pharmacokinetics of once daily maraviroc (MVC) co-administered as part of a novel nucleoside- sparing regimen with atazanavir/ritonavir in treatment-naive HIVinfected patients. Rev. Antivir. Ther. Infect. Dis. 2:36.
23. Okoli C, Siccardi M, Thomas-William S, Dufty N, Khonyongwa K, Ainsworth J, Watson J, Cook R, Gandhi K, Hickinbottom G, Owen A, Taylor S. 2012. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. J. Antimicrob. Chemother. 67:671-674.
24. Wire MB, Shelton MJ, Studenberg S. 2006. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45:137-168.
25. Taylor S, Arribas JR, Perno CF, Burnside R, McFadyen L, Hardy D, Stellbrink H-J, Cooper DA, Molina J-M, van der Ryst E, Heera J, Valdez H. 2011. Efficacy of maraviroc (MVC) administered once daily (QD) or twice daily (BID) with boosted protease inhibitors (bPIs) to treatmentexperienced patients. 6th Int. AIDS Conf. HIV Pathog. Treatment Prevention, abstr TUAB0106.
26. van der Ryst E, Cooper D, Konourina I, Saag M, Goodrich J, Tawadrous M, Simpson P, Sullivan J, Westby M, Mayer H. 2007. Efficacy of maraviroc in combination with at least one other potent new antiretroviral drug: 24-week combined analysis of the MOTIVATE 1 and 2 studies. 4th Int. AIDS Soc. Conf. HIV Pathog. Treatment Prevention, poster WEPEB115LB.
27. McFadyen L, Jacqmin P, Wade JR, Weatherley B. 2008. Maraviroc exposure-efficacy analysis in HIV-1-infected treatment-naive subjects: ITT population (MERIT Study). XVII Int. AIDS Conf., poster TUPE0053.
28. Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, Muirhead GJ. 2008. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br. J. Clin. Pharmacol. 65(Suppl 1):5-18.
29. Vourvahis M, Fang J, Choo HW, Heera J. 2011. Lack of a clinically relevant effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers. 12th Int. Workshop Clin. Pharmacol. HIV Ther., poster 14.
30. ViiV Healthcare. 2011. Prescribing information for LEXIVA (fosamprenavir). ViiV Healthcare, Middlesex, United Kingdom. http://viivhealthcare.com/products/lexiva-telzir#.
31. ViiV Healthcare. 2011. Telzir (fosamprenavir): summary of product characteristics. ViiV Healthcare, Middlesex, United Kingdom. http://viivhealthcare.com/products/lexiva-telzir#.
32. AbbVie, Inc. 2013. Prescribing information for Norvir (ritonavir). AbbVie, North Chicago, IL. http://www.rxabbvie.com/pdf/norvirtab-pi.pdf.
33. Gathe JC, Jr, Ive P, Wood R, Schurmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J. 2004. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18:1529-1537.
34. GlaxoSmithKline. 2013. GKS clinical study register: results summary for APV30003. GlaxoSmithKline, Brentford, United Kingdom. http://www.gsk- clinicalstudyregister.com/result-detail.jsp?protocolId-APV30003&studyId- BBF50164-7E7F-461F-B135-141D187FBC6D&compound-APV30003&type-GSK-Study- ID&letterrange-All.